Clinical Trial Update: A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML [Phase 1]

View source ↗

Summary

Phase 1 trial to assess the safety and tolerability of Ziftomenib in combination with Venetoclax/Azacitidine, Venetoclax alone, or 7+3 with Quizartinib in patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Kmt2a Rearrangement
• Acute Myeloid Leukemia with Npm1 Mutation
• Myeloid Sarcoma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Quizartinib (Quizartinib)
• Venetoclax (venetoclax)
• Ziftomenib (ziftomenib)

Snippet

Sponsor: Kura Oncology, Inc. | Conditions: Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation | Phase 1 | Status: RECRUITING